N-Acetyl Semax (25mg)

$57.00

Size: 25mg
Contents: N-Acetyl Semax
Form: Lyophilized powder
Purity: >99%
SKU: N-Acetyl-Semax

FREE Shipping on $200+ orders

FREE Bacteriostatic Water (30ml) on $200+ orders

Discount per Quantity

QuantityDiscountPrice
5 - 85%$54.15
9 +10%$51.30
SKU: N-Acetyl-Semax Category:

N-Acetyl Semax Peptide

N-Acetyl Semax is a synthetic polypeptide analogous to the naturally occurring adrenocorticotropic hormone (ACTH). The peptide is similar to this ACTH hormone fragment 4-10 (ACTH 4-10).(1) N-Acetyl Semax appears to exhibit efficient nootropic (memory enhancing) and neuroprotective properties.

The N-Acetyl Semax peptide appears to produce action via three routes:

  • By potentially inhibiting specific enzymes such as enkephalins and peptide degrading enzymes(2)
  • By potentially increasing dopamine and brain-derived neurotrophic (BDNF) levels(3)
  • By potentially modulating gene expression and increasing the efficacy of the immune system(4)

Chemical Makeup(5)

Molecular Formula: C37H51N9O10S
Molecular Weight: 813.9 g/mol
Other known titles: ACTH (4-7), HY-P1146

 

Research and Clinical Studies

N-Acetyl Semax and Nootropic Potential

A study(6) was conducted on experimental rodents to determine the nootropic potential of ACTH hormone and its analogs, such as Semax. After presenting Semax, all tested rodents were examined for 5-hyrodxyindoleacetic acid (5-HIAA) levels. Based on the results, it was noted that the 5-HIAA levels increased by 25% after just 2 hours of Semax; and increased progressively up to a maximum of 180% after 4 hours of peptide. As per Kirill O Eremin et al., “Our results reveal the positive modulatory effect of Semax on the striatal serotonergic system and the ability of Semax to enhance both the striatal release of dopamine and locomotor behavior elicited by D-amphetamine.”

In a clinical research study(7)  male subjects undergoing excessive stress were given Semax. Upon analyzing subject behavior 24 hours after the peptide, it was noted that they appeared to show signs of enhanced memory and attention. As per the reports, "In the majority of cases, the peptide exhibited positive effects, and in no case it produced negative side actions or complications connected with its administration. There is good reason to believe that medical potentialities of semax have not been exhausted and in the future new possibilities of its usage will be revealed." The study is shared here for educational and research purposes, and studies on the Semax peptide are still being conducted.

N-Acetyl Semax and SSRI Interaction

Selective Serotonin reuptake inhibitors (SSRIs) are a class of antidepressants, sometimes prescribed to pregnant women. These compounds may risk passing through the placenta and impacting fetal brain development. In a pre-clinical research study(8), experimental rats aged between 1 and 14 days were presented first with an SSRI compound, followed by the Semax peptide. After 4 weeks, it was observed that the rats given SSRIs showcased apparently anxious behavior, especially when exposed to new items. When given the Semax peptide, these same rats later reportedly exhibited enhanced learning abilities and reduced anxiety.

N-Acetyl Semax and Separation Anxiety

Young infants face separation anxiety when they are away from their mothers. Separating for a prolonged period may lead to impaired emotional reactivity. A research study(9) examined young experimental rats facing maternal deprivation. After four weeks of separation from their mothers, these rats reportedly exhibited increased anxiety and excessive physical activity. When the rats were presented with Semax, their reactions improved, indicating reduced anxiety. As per M A Volodina et al., these results suggest that “Semax [weakens] the impact of deprivation on animal body weight and [normalizes] the levels of anxiety in rats.”

N-Acetyl Semax and the Cardiovascular System

For this study(10), experimental rodents were induced with myocardial infarction (MI), which can potentially lead to vascular damage. These rodents were then divided into two groups – one was given Semax peptide for six days, and the second was given a placebo. 28 days after the occurrence of myocardial infarction, it was reported by the researchers that the control rodents appeared to exhibit reduced arterial blood pressure and cardiac hypertrophy, both of which may signal impending heart failure. In contrast, the peptide rodents reportedly exhibitied signs of prevention of diastolic blood pressure, which may indicate possible remodeling of the heart ventricle and inhibition of heart failure.

N-Acetyl Semax and Neuroprotection

In a clinical study(11), 100 subjects with ischemic strokes were enrolled for 10 days. Of these, 30 patients were presented with conventional compounds and the Semax peptide, while the rest were presented with conventional compounds only. After 10 days, all subjects were examined via electroencephalogram (EEG). Based on the EEG mapping, it was reported by the researchers that the subjects presented with both the peptide and compound exhibited apparently notable improvement in restoring damaged brain activity.

N-Acetyl Semax peptide is available for research and laboratory purposes only. Please review and adhere to our Terms and Conditions before ordering.

References

  1. T. Kolomin et al., A New Generation of Drugs: Synthetic Peptides based on Natural Regulatory peptides. Neuroscience & Medicine, 2013, 223-252. Published Online December 2013. http://dx.doi.org/10.4236/nm.2013.44035
  2. Kost NV, Sokolov OIu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Ingibiruiushchee deĭstvie semaksa i selanka na énkefalindegradiruiushchie fermenty syvorotki krovi cheloveka [Semax and selank inhibit the enkephalin-degrading enzymes from human serum]]. Bioorg Khim. 2001 May-Jun;27(3):180-3. Russian. doi: 10.1023/a:1011373002885. PMID: 11443939. https://pubmed.ncbi.nlm.nih.gov/11443939/
  3. Shih-Jen Tsai, Semax, an analogue of adrenocorticotropin (4–10), is a potential agent for the treatment of attention-deficit hyperactivity disorder and Rett syndrome, Medical Hypotheses, Volume 68, Issue 5, 2007, Pages 1144-1146. https://doi.org/10.1016/j.mehy.2006.07.017
  4. Medvedeva, E.V., Dmitrieva, V.G., Povarova, O.V. et al. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics 15, 228 (2014). https://doi.org/10.1186/1471-2164-15-228
  5. National Center for Biotechnology Information (2023). PubChem Compound Summary for CID 9811102, Semax.
  6. Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005 Dec;30(12):1493-500. doi: 10.1007/s11064-005-8826-8. PMID: 16362768. https://pubmed.ncbi.nlm.nih.gov/16362768/
  7. Asmarin IP, Nezavibat'ko VN, Miasoedov NF, Kamenskiĭ AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIa, Koshelev VB, Riasina TV. Nootropnyĭ analog adrenokortikotropina 4-10-semaks (15-letniĭ opyt razrabotki i izucheniia) [A nootropic adrenocorticotropin analog 4-10-semax (l5 years experience in its design and study)]. Zh Vyssh Nerv Deiat Im I P Pavlova. 1997 Mar-Apr;47(2):420-30. Russian. PMID: 9173745. https://pubmed.ncbi.nlm.nih.gov/9173745/
  8. Nataliya Yu. Glazova, Daria M. Manchenko, Maria A. Volodina, Svetlana A. Merchieva, Ludmila A. Andreeva, Vladimir S. Kudrin, Nikolai F. Myasoedov, Natalia G. Levitskaya, Semax, synthetic ACTH(4–10) analogue, attenuates behavioural and neurochemical alterations following early-life fluvoxamine exposure in white rats, Neuropeptides, Volume 86, 2021, 102114, ISSN 0143-4179. https://doi.org/10.1016/j.npep.2020.102114
  9. Volodina MA, Sebentsova EA, Glazova NY, Levitskaya NG, Andreeva LA, Manchenko DM, Kamensky AA, Myasoedov NF. Semax attenuates the influence of neonatal maternal deprivation on the behavior of adolescent white rats. Bull Exp Biol Med. 2012 Mar;152(5):560-3. English, Russian. doi: 10.1007/s10517-012-1574-2. PMID: 22803132. https://pubmed.ncbi.nlm.nih.gov/22803132/
  10. Gavrilova SA, Golubeva AV, Lipina TV, Fominykh ES, Shornikova MV, Postnikov AB, Andrejeva LA, Chentsov IuS, Koshelev VB. [Protective effect of peptide semax (ACTH(4-7)Pro-Gly-Pro) on the rat heart rate after myocardial infarction]. Ross Fiziol Zh Im I M Sechenova. 2006 Nov;92(11):1305-21. Russian. PMID: 17385423. https://pubmed.ncbi.nlm.nih.gov/17385423/
  11. Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. Effektivnost' semaksa v ostrom periode polusharnogo ishemicheskogo insul'ta (klinicheskoe i élektrofiziologicheskoe issledovanie) [Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study)]. Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. Russian. PMID: 11517472. https://pubmed.ncbi.nlm.nih.gov/11517472/

Dr. Marinov

Dr. Marinov (MD, Ph.D.) is a researcher and chief assistant professor in Preventative Medicine & Public Health. Prior to his professorship, Dr. Marinov practiced preventative, evidence-based medicine with an emphasis on Nutrition and Dietetics. He is widely published in international peer-reviewed scientific journals and specializes in peptide therapy research.

0
    Your Cart
    Your cart is empty